Evidence map›Paper›PMID 42530576›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Prognostic value of volume-based metabolic parameters of [

H I Coerts, O P Smit, J F Lin, P van Houten, T P Links, A H Brouwers, C C D van der Rijt, T M van Ginhoven, R T Netea-Maier, M J C van Treijen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

H I CoertsAcademic Center for Thyroid Diseases, Department of Radiology and Nuclear Medicine, Erasmus Medical Centre Rotterdam, P.O. 2040, Doctor Molewaterplein 40, 3015 GD , CA, 3000, Rotterdam, the Netherlands.
O P SmitAcademic Center for Thyroid Diseases, Department of Radiology and Nuclear Medicine, Erasmus Medical Centre Rotterdam, P.O. 2040, Doctor Molewaterplein 40, 3015 GD , CA, 3000, Rotterdam, the Netherlands.
J F LinDepartment of Surgical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
P van HoutenDepartment of Internal Medicine, Division of Endocrinology, Radboud University Nijmegen Medical Center, PO Box 9101, Nijmegen, 6500HB, the Netherlands.
T P LinksDivision of Endocrinology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
A H BrouwersDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
C C D van der RijtAcademic Center for Thyroid Diseases, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
T M van GinhovenAcademic Center for Thyroid Diseases, Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, 3015GD, The Netherlands.
R T Netea-MaierDepartment of Internal Medicine, Division of Endocrinology, Radboud University Nijmegen Medical Center, PO Box 9101, Nijmegen, 6500HB, the Netherlands.
M J C van TreijenDepartment of Endocrine Oncology, University Medical Center Utrecht, Utrecht, 3584 CX, the Netherlands.
M MediciAcademic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
B de KeizerDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, 3584 CX, the Netherlands.
S KruijffDepartment of Surgical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
F A VerburgAcademic Center for Thyroid Diseases, Department of Radiology and Nuclear Medicine, Erasmus Medical Centre Rotterdam, P.O. 2040, Doctor Molewaterplein 40, 3015 GD , CA, 3000, Rotterdam, the Netherlands. f.verburg@erasmusmc.nl.ORCID http://orcid.org/0000-0002-7161-0979

Funding

KWF Kankerbestrijding 14129
6 · The paper itself

Abstract

introductionAnaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with a median overall survival (OS) of approximately 2 months. The prognostic value of

methodsThis retrospective study analyzed 34 patients diagnosed with ATC between January 2010 and October 2024 who underwent initial staging with [

resultsOS was 48 days (IQR: 27-134). In univariate analysis, MTV (HR = 1.44, p = 0.009) was significantly associated with poorer OS. Surgery was associated with a significantly decreased hazard of mortality (HR, 0.418; 95% CI, 0.188-0.929; P = 0.032), as was radiotherapy (HR, 0.423; 95% CI, 0.220-0.977; P = 0.026).

conclusionThis study identifies MTV as a significant prognostic markers in univariate analysis for patients with ATC, highlighting the utility of [

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyThyroid Carcinoma, AnaplasticTumor BurdenAgedFemaleGlycolysisHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsRetrospective StudiesThyroid NeoplasmsFluorodeoxyglucose F18RadiopharmaceuticalsAnaplastic Thyroid CarcinomaFDG PET/CTMetabolic tumor volumePrognosisTotal lesion glycolysis

Identifiers

PMID42530576
PMCPMC13633364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.